Table 6.

Preliminary clinical data of DDR targeting agents in platinum resistant or refractory ovarian cancer

NCT	NCT02595892	NCT04497116	NCT01164995	NCT02151292	NCT03579316a	NCT04516447	NCT02203513	NCT02632448
Drugs	Berzosertib + Gemcitabine vs Gemcitabine	Camonsertib	Adavosertib+ Carboplatin	Adavosertib + Gemcitabine vs Gemcitabine	Adavosertib vs Adavosertib + Olaparib	Azenosertib+chemotherapy	Prexasertib	LY2880070+Gemcitabine
No. of patients	34 vs 36	20	23	61 vs 33	35 vs 35	56	49	27
Confirmed % of BRCA mutant or HRD	18% vs 14%	85%	9% BRCA1 mutation	16% vs 12%	48% BRCA mutation	Not reported	BRCA wildtype	Not reported
% of prior PARPi treatment	32% vs 19%	90%	Not reported	Not reported	100%	14%	46%	Not reported
% of prior bevacizumab treatment	29% vs 25%b	Not reported	4%	Not reported	Not reported	46%	81%	Not reported
ORR (%)	3% vs 11%	1 CR, 3 PRs, 1 CA125 response	43% (95% CI, 22% - 66%)	23% vs 6%	23% (90% CI, 12% – 38%) vs 29% (16% – 44%)	Total 30.2%; ZnC3+paclitaxel: 62.5%; ZnC3+carboplatin: 45.5% ZnC3+PLDc: 12.5%	30.7%	7.4%
mPFS	22.9 weeks (90% CI 17.9–72.0) vs 14.7 weeks (9.7–36.7), hazard ratio 0.57, 0.33–0.98; one-sided log-rank test p = 0.044	Not reported	5.3 months (95% CI, 2.3 to 9.0 months)	4.6 months (95% CI 3.6–6.4) vs 3.0 months (1.8–3.8), hazard ratio 0.55 [95% CI 0.35–0.90]; log-rank p = 0·015	5.5 months (90% CI, 3.9–6.9) vs 6.8 months (4.3–8.3)	Not reported	5.8 months (range 1.7-26.4 months).	Not reported
mOS	59.4 weeks (90% CI 33.7–84.4) vs 43.0 weeks (34.4–67.9) hazard ratio 0.84, 0.53–1.32; one-sided log-rank test p = 0.26	Not reported	12.6 months (95% CI, 4.9 to 19.7),	11.4 months (95% CI 8.2–16.5) vs 7.2 months (5.2–13.2); hazard ratio 0.56 [95% CI 0.35–0.91]; log-rank p = 0.017	Not reported	Not reported	Not reported	Not reported

^aA two-arm noncomparative trial

^bPrevious antiangiogenic therapy

^cPLD: Pegylated liposomal doxorubicin